AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 52 min read$XRAY

Earnings To Watch: Dentsply Sirona (XRAY) Reports Q2 Results Tomorrow

Dentsply Sirona (XRAY) will report Q2 results Thursday after market hours. The company previously reported $880M revenue, flat year over year, and EPS that beat full-year guidance estimates. For the upcoming quarter, analysts expect revenue to fall 4.6% y/y. The article cites an average analyst price target of $13.44 versus $14.25 current.

Original reporting
financialcontent.com
Published Aug 5, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Earnings To Watch: Dentsply Sirona (XRAY) Reports Q2 Results Tomorrow — source image
Source · financialcontent.com
Decision brief

The 30-second read

$XRAYNeutralMed
01

Why it matters

Traders can use the consensus revenue decline expectation and peer results as a short-term volatility map, but there is no new company-specific financial disclosure in the text itself.

02

Market read

This is a pre-earnings positioning brief for XRAY, centered on consensus revenue expectations and peer read-throughs.

03

What to watch

The article does not discuss margins, guidance details, or any specific operational drivers that typically determine post-earnings repricing.

Relevance 4/10Novelty 4/10Timing: pre-market positioning ahead of Thursday after-hours earnings

Background

The article frames Dentsply Sirona’s upcoming Q2 earnings, referencing last quarter’s revenue beat and the market’s expectation for another YoY revenue decline.

Company-level read

Ticker impact

$XRAYNeutralMedium confidence
Context

Dentsply Sirona is scheduled to report Q2 results after the close this Thursday, with the article citing consensus revenue decline and recent estimate reconfirmations.

Expected impact

Likely volatility around the print versus the expected 4.6% YoY revenue decline, with direction dependent on whether results beat or miss consensus.

Evidence & confidence

The text is a pre-earnings setup using consensus and peer read-throughs, not a fresh disclosure like guidance, a contract, or a regulatory action.

Market effects

Sector

Healthcare equipment and supplies names are being used for read-through (Henry Schein, Align Technology), implying traders may trade the group on relative beats/misses.

Regional

Primarily US-focused as the catalyst is a US-listed earnings release.

Global

Limited, since the article does not cite global regulatory, supply-chain, or macro shocks.

Counterpoint

What could challenge this read

If the company’s prior-quarter pattern of beating revenue expectations repeats, the stock could outperform despite the consensus YoY decline.

Key entities

  • company
    Dentsply Sirona

    NASDAQ-listed dental products company reporting Q2 results after market hours this Thursday.

  • company
    Henry Schein

    Peer cited as having reported Q2 revenue growth and a beat versus expectations.

  • company
    Align Technology

    Peer cited as having reported revenues in line with consensus and trading down after results.

Read at source← All news

Related articles

AUG 7
$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

financialcontent.com3 min
AUG 7
$XRAYMedAI 8/10

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Dentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.

tradingview.com6 min
AUG 8
$SHOPMedAI 8/10

Shopify Was Supposed to Be an AI Casualty. Its AI-Referred Traffic Just Tripled.

Shopify (SHOP) reported Q2 results, citing AI-referred traffic to merchants’ storefronts that tripled year over year and orders that began with AI search also tripled. New buyers from AI channels placed orders at nearly twice the rate of other channels. Revenue rose 34% to $3.6B, GMV reached $115.6B, operating income rose 68% to $488M, and free cash flow was $654M.

yahoo.com6 min
AUG 8
$GPRKMed

Geopark Q2 Earnings Call Highlights

Geopark (NYSE:GPRK) reported Q2 earnings call updates. It plans $40m to $50m of Vaca Muerta investment in 2H 2026 after $55m in 1H, with 70% to 80% in Q3. Full-year lifting costs are guided at $17 to $19/bbl. Cash rose to $316m, net leverage fell to 1.2x EBITDA, and a $0.023/share quarterly dividend was declared.

yahoo.com6 min
AUG 8
$GRDNMed

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.

yahoo.com5 min